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Abstract 
Background: Coronary artery disease (CAD) is characterized by narrowing/ blockade of coronary arteries that is 
mainly caused by atherosclerotic plaques. Considering the involvement of platelet abnormalities, such as defective 
aggregation and adhesion, in the cardiovascular-related disorders, genetic variations in human platelet alloantigens 
(HPA) have been implicated in the CAD susceptibility. Herein, we intended to determine the association of HPA-1 to 
-6, -9, and -15 biallelic polymorphisms with CAD in an Iranian population.
Methods: In this retrospective case–control study, 200 CAD subjects and 100 matched healthy individuals were 
enrolled. DNA samples were isolated from peripheral blood samples and genotyping of HPA polymorphisms was 
accomplished using polymerase chain reaction-sequence-specific primers.
Results: The alleles and genotypes of studied HPA polymorphisms were equally distributed among cases and con-
trols and therefore no statistically significant differences were detected. Univariate analysis identified no association of 
combined haplotypes with CAD risk. However, multivariate analysis showed a positive association of the HPA1b/2a/3b 
haplotype with CAD after adjustment for some covariates (including BMI, TG, LDL, FBS and blood pressure) that con-
ferred a CAD susceptibility haplotype (P = 0.015; OR = 2.792; 95% CI 1.45–8.59).
Conclusions: Although alleles, genotypes, and haplotypes of HPA polymorphisms were not associated with CAD risk, 
HPA1b/2a/3b haplotype was found to be a dependent disease risk haplotype in Iranian population after correcting for 
confounding factors.
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Background
Coronary artery disease (CAD) is a leading cause of mor-
tality and morbidity in the globe. According to a report 
in 2014, about 17.5 million individuals died due to CAD 
[1], in which approximately 80% of death cases occurred 
in the countries with low/middle-income economy [2]. 
CAD in considered as a common disease of the vas-
cular system and is defined by prolonged atheroscle-
rotic lesions that eventuate in narrowing and ultimately 
obstructing the coronary arteries, resulting in tissue 
injury. The most critical manifestations of the CAD are 
myocardial infarction (MI) and angina, with the ulti-
mate development of thrombosis of coronary arteries 
and rupture of the plaques [3]. Currently, many risk fac-
tors have been reported to be involved in susceptibility 
to CAD. More than 250 genes play critical roles in CAD 
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predisposition that are involved in increasing or decreas-
ing risks of CAD [4–6].
Evidence show that impaired aggregation and adhesion 
of platelets might be underlying contributing factor in the 
progression of coronary syndrome. Additionally, genetic 
polymorphisms in human platelet antigens (HPAs) have 
been recognized to be associated with susceptibility to 
CAD [7]. Receptors of the membrane glycoproteins (GP) 
on the platelets are involved in the activation, aggrega-
tion, and adhesion of platelets, the serialized occurrences 
that culminate in thrombus formation and development 
of acute coronary syndrome (ACS) [8–10]. Most of the 
known HPA (20 of 33) are located on the GPIIb/IIIa 
complex, while the remaining 13 HPAs are expressed on 
other GP complexes of the platelet, including GPIb/IX/V, 
GPIa/IIa and CD109 [11]. Several studies have indicated 
an association between multiple genetic polymorphisms 
harbored by the genes coding the platelet GPs with dys-
regulated functions of the platelets, such as promoted 
platelet adhesion and aggregation, and therefore increase 
the risk of CAD [12].
Studies have reported the role of HPA-1, HPA-2, and 
HPA-3 in development of disorders associated with 
blood clotting and platelet aggregation, hence confer-
ring a risk for the onset of cardiovascular diseases [11]. In 
addition, most of the GPs on the platelets (such as GPIIb/
IIIa) have been shown to harbor these SNPs [13].
Previous studies are inconsistent with the association 
of HPA-1b/2a/3b alleles, genotypes, haplotypes, and 
traditional risk factors with CAD. The observed conflict 
in the results of different studies may stem from diag-
nostic criteria in determination of the CAD patients, 
genetic detection techniques, and adjustment of genetic 
polymorphisms to other risk factors of CAD. Moreover, 
differences in genetic stratifications in different ethnic 
populations may also be involved in the incongruent 
results. This study evaluated most important HPA poly-
morphisms (HPA-1, HPA-2, HPA-3) as well as those with 
little considerations in previous studies (HPA-4, HPA-5, 
HPA-6, HPA-9, and HPA-15) in association with CAD 
susceptibility in an Iranian population.
Study subjects and methods
Patients and controls
The current retrospective case–control study, compris-
ing 200 unrelated Iranian patients with CAD, consisted 
of 124 males and 76 females (mean age of 62.21 ± 9.48). 
The subjects were selected consecutively from individu-
als who referred to the Rajaei Heart Hospital, Tehran, 
Iran between January 2018 until August 2019. As the 
control group, 100 healthy and unrelated Iranian indi-
viduals, consisting of 55 males and 45 females (mean 
age of 57.74 ± 10.5), who attended to Masoud Medical 
Laboratory, Tehran, Iran for a routine checkup, were 
included in the study. The healthy control subjects did 
not have autoimmune and inflammatory diseases, can-
cers, metabolite disorders, and immunodeficiencies, nei-
ther in themselves nor their immediate family members.
The diagnosis of CAD was accomplished in accordance 
with the visual evaluation of the coronary angiogram by 
cardiologist. A threshold of luminal narrowing greater 
than 50% in diameter seen in minimum one of the main 
coronary arteries or related main branches was regarded 
as validation for diagnosis of CAD. The clinical history of 
patients, such as risk factors related to the cardiovascu-
lar development, was obtained from CAD patients. The 
scores for blood pressure, glucose, and lipid profile were 
obtained from the medical records at the time of diagno-
sis, when the subjects were detected for CAD but were 
not under medication. Furthermore, there was a number 
of subjects that were newly diagnosed, which were also 
not under drug regimen for controlling blood pressure, 
glucose, and lipid profile. The patients were assessed for 
the presence of diabetes mellitus based on a raised fasting 
blood glucose (FBS) > 130 mg/dl. Individuals with a body 
mass index (BMI), which was determined through body 
weight divided by height squared (kg/m2), of higher than 
30 was considered as obese patients. To determine the 
hypertension in the study participants, the seated blood 
pressure (BP) was measured (> 140/90 mmHg on two dif-
ferent occasions). Hypercholesterolemia was defined as 
a total cholesterol level above 200  mg/dl. Baseline fea-
tures of the patients and healthy control individuals are 
described in detail in Table 1.
The local ethical committee of Iran University of Medi-
cal Sciences, Tehran, Iran approved the protocol of the 
study. Before sampling, all study participates signed the 
informed consent forms. Upon an overnight fasting, 
peripheral blood samples were obtained from all patients 
and control subjects in EDTA-treated vacuum tubes.
Genotyping of HPA polymorphisms by PCR‑SSP
The DNA content was extracted from blood samples by 
the salting-out approach [14]. After dissolving the DNAs 
with RNase-free water, samples were stored at 4  °C for 
pending assays. In order to genotype eight HPA poly-
morphisms [including HPA-1 T196C (rs5918), HPA-2 
C524T (rs6065), HPA-3 T2622G (rs5911), HPA-4 G526A 
(rs5917), HPA-5 G1648A (rs1062535), HPA-6 A1564G 
(rs13306487), HPA-9 A2603G (rs137852907), and HPA15 
A2108G (rs10455097)], the polymerase chain reaction 
with sequence-specific primers (PCR-SSP) approach 
was employed, as already described [15]. The detec-
tion of two different alleles through PCR-SSP technique 
depends on the Taq polymerase inability to repair a sin-
gle base mismatch located in the 3′-end of a primer. The 
Page 3 of 9Malakootikhah et al. BMC Cardiovasc Disord           (2021) 21:68  
amplification of the target region is happened if a com-
plementary matching of the 3′-end of primer occurred 
to the sequence at the allelic polymorphism region. Oth-
erwise, mismatching of the primer and sequence of the 
allelic variation leads to no amplification. Wild-type and 
variant HPA alleles for each locus were assigned as “a” 
and “b”, respectively. The thermocycling program of the 
PCR were: 1 cycle of 95 °C for 2 min, then followed by 10 
cycles of 95 °C for 10 s and 65 °C for 1 min, then 20 cycles 
of 95 °C for 10 s, 61 °C for 50 s and 72 °C for 30 s, finally 
holding at 4  °C. The thermocycling conditions of the 
PCR were in accordance of the previous recommenda-
tion, with slight alterations on the annealing temperature 
of the primers (Table 2). In order to detect each allele of 
the HPA polymorphisms, two sets of primers, one for 
allele-specific and another for the common allele, were 
employed (Table 2) [16]. After performing electrophore-
sis of the amplified samples on the agarose gel (2% w/v) 
stained with DNA safe stain, discrimination of the alleles 
was conducted through direct observation of the prod-
ucts. Figure 1 illustrates the electrophoretic bands related 
to each allele of the determined HPA polymorphisms.
Statistical analysis
The gene-counting approach was used to determine 
the frequency of the alleles for each polymorphism of 
HPAs. The Fisher’s exact or Pearson’s chi-squared tests 
was implemented in order to determine the deviation of 
genotype frequencies in the control group from Hardy–
Weinberg equilibrium (HWE). Univariate and then mul-
tivariate logistic linear regression analyses were employed 
to calculate the odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs). The differences in the frequen-
cies of the allele and genotype of HPA polymorphisms 
were determined using Fisher’s exact or Pearson’s chi-
squared tests. The expectation maximization approach 
was carried out in order to estimate the HPA haplotypes 
using the online SHEsis software [17]. The correction of 
P values in more than 2 comparisons was conducted by 
the Bonferroni method. The relative risks were adjusted 
for the confounding variables, such as diabetes mellitus, 
hypertension, BMI, total cholesterol, and triglycerides. 
The difference between numerical variables was deter-
mined through Mann–Whitney U test to compare the 
means between CAD patients and healthy controls. A 
P value < 0.05 was regarded as the statistical level of sig-
nificance. The data analysis was conducted using SPSS 
v.22 software. Presentation of data was done through 
mean ± standard deviation (SD) and percentage fraction 
of the total value for continuous and nominal variables, 
respectively.
Results
Frequency of the allele and genotypes of the HPA 
polymorphisms
Table 3 shows the frequency of the alleles and genotypes 
of each HPA polymorphism in both patient and control 
groups. No deviation from HWE was detected for the 
genotype distribution of the HPA polymorphisms in the 
control group.
The distribution of the HPA alleles and genotypes did 
not show significant differences between CAD patient 
and healthy control groups. It was observed that the 
HPA-15b allele frequency was the highest in patients and 
Table 1 Characteristics of study participants
CAD chronary artery disease, BP blood pressure, BMI body mass index, FBS fasting blood sugar, TG triglyceride, HDL high-density lipoprotein, LDL low-density 
lipoprotein
a Mann-Whitney U test
b Pearson’s chi-square test
*Both currently active and subjects with history of smoking (at least 2 years) were included
Variables CAD patients (n = 200) Controls (n = 100) P value
Age (years) (mean ± SD) 62.21 ± 9.48 57.74 ± 10.5 0.272a
Gender (M/F) (%) 124 (62)/76 (38) 55 (55)/45 (45) 0.184b
Smokers (%)* 76 (38) 14 (14) 0.070b
Systolic BP (mmHg) (mean ± SD) 142.4 ± 16.91 119.3 ± 9.58 0.000a
Diastolic BP (mmHg) (mean ± SD) 88.7 ± 14.7 79.1 ± 11.1 0.090a
BMI (kg/cm2) (mean ± SD) 48.02 ± 4.12 27.06 ± 3.60 0.041a
FBS (mg/dl) (mean ± SD) 119.90 ± 43.44 95.14 ± 8.85 0.000a
Total Cholesterol (mg/dl) (mean ± SD) 295.39 ± 40.80 174.65 ± 27.16 < 0.001a
TG (mg/dl) (mean ± SD) 176.66 ± 90.84 122.91 ± 33.81 < 0.001a
HDL (mg/dl) (mean ± SD) 38.83 ± 9.90 57.15 ± 12.32 0.000a
LDL (mg/dl) (mean ± SD) 201.43 ± 24.91 88.88 ± 27.78 < 0.001a
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healthy control subjects. The homozygous HPA-15b/15b 
and HPA-3b/3b genotypes were detected in high preva-
lence in patient and healthy control groups. The frequen-
cies of the alleles and genotypes of HPA-4b, HPA-6b, and 
HPA-9b polymorphisms were not seen to have any differ-
ences between patients and controls, and therefore were 
omitted from further analysis (Table 3).
Haplotype frequencies
The analysis of haplotype was based on three variants, 
including HPA1, HPA2, and HPA3. Among the eight 
identified HPA haplotypes, none of them indicated sta-
tistically significant differences between CAD patients 
and controls. In addition, upon performing the Bonfer-
roni correction, it was observed that the differences were 
not significant for HPA haplotypes between patients and 
control subjects (Table 4).
Regression analysis
The frequency of all potential haplotypes did not show 
statistically significant differences between CAD patients 
and healthy controls, according to the univariate regres-
sion analysis (Table 5). However, when the HPA-1a/2a/3a 
haplotype was considered as reference (OR = 1.00), there 
was a statistically significant association of HPA-1b/2a/3b 
(P = 0.015, OR = 2.792, 95% CI 1.45–8.59) with CAD risk 
in the multivariate regression analysis upon adjusting for 
the confounding factors (Table 5).
Table 2 Primer sequences, mixes, and their specificities in PCR-SSP assay
Primers Sequences Annealing 
temperature (°C)





5ʹ-ACT TAC AGG CCC TGC CTC T-3ʹ
5ʹ-ACT TAC AGG CCC TGC CTC C-3ʹ




HPA-1a + common, 0.5 µM





5ʹ-CCC CCA GGG CTC CTGAC-3ʹ
5ʹ-GCC CCC AGG GCT CCT GAT -3ʹ




HPA-2a + common, 0.5 µM





5ʹ-GGG GGA GGG GCT GGGGA-3ʹ
5ʹ-GGG GGA GGG GCT GGGGC-3ʹ




HPA-3a + common, 0.5 µM





5ʹ-GCT GGC CAC CCA GAT GCG -3ʹ
5ʹ-AGC TGG CCA CCC AGA TGC A-3ʹ




HPA-4a + common, 0.5 µM





5ʹ-AGT CTA CCT GTT TAC TAT CAAAG -3ʹ
5ʹ-AGT CTA CCT GTT TAC TAT CAAAA -3ʹ




HPA-5a + common, 2 µM





5ʹ-GAC GAG TGC AGC CCCCG-3ʹ
5ʹ-GGA CGA GTG CAG CCC CCA -3ʹ




HPA-6a + common, 0.5 µM





5ʹ-GGG CAG CCC CCA GTC CAC -3ʹ
5ʹ-GGG CAG CCC CCA GTC CAT -3ʹ




HPA-9a + common, 0.5 µM





5ʹ-TTC AAA TTC TTG GTA AAT CCTGT -3ʹ
5ʹ-TTC AAA TTC TTG GTA AAT CCTGG -3ʹ




HPA-15a + common, 2 µM




5ʹ-GCC TTC CCA ACC ATT CCC TTA-3ʹ
5ʹ-TCA CGG ATT TCT GTT GTG TTTC-3ʹ
64
62
HGH (F + R), 0.2 µM 429
DRα-F
DRα-R
5ʹ-GAG GTA ACT GTG CTC ACG AAC AGC -3ʹ
5ʹ-CAC GTT CTC TGT AGT CTC TGGG-3ʹ
74
68
DRα (F + R), 0.2 µM for HPA-5
DRα (F + R), 0.1 µM for HPA-15
607
Fig. 1 Gel electrophoresis of PCR-SSP products for HPA genotyping. 
Representative typing result revealing identification of homozygous 
a/a (HPA 1, 4, 5, 6 and 9) heterozygous a/b (HPA 2, 3 and 15). The 
upper arrow indicates a 429 bp of human growth hormone gene 
as internal amplification control for HPA 1,2,3,4,6,9 and a 607 bp of 
DRα gene as internal control for HPA 5 and 15, while the lower arrow 
indicates specific HPA allele. Full-length gel images are presented in 
Additional file 1: Fig. 1
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Table 3 Allele and genotype distribution of HPA polymorphisms in CAD patients and healthy controls
SNP single nucleotide polymorphism, CAD coronary arthery disease, HWE Hardy–Weinberg equilibrium
dbSNP Alleles/genotypes CAD (n = 200)
N (%)
Control (n = 100)
N (%)
χ2 P value OR (95% CI)
HPA1 T (a) 363 (90.7) 178 (89) 0.460 0.497 1.212 (0.69–2.11)
C (b) 37 (9.3) 22 (11) – – 0.824 (0.47–1.43)
TT (aa) 163 (81.5) 79 (78) 0.516 0.472 1.242 (0.68–2.24)
CT (ab) 37 (18.5) 22 (22) – – 0.804 (0.44–1.45)
CC (bb) 0 (0) 0 (0) – – –
HWE P = 0.216
HPA2 C (a) 350 (87.5) 178 (89) 0.284 0.594 0.865 (0.50–1.47)
T (b) 50 (12.5) 22 (11) – – 1.155 (0.67–1.96)
CC (aa) 153(76.5) 79 (79) 0.303 0.859 0.865 (0.48–1.54)
CT (ab) 44 (22) 20 (20) – – 1.128 (0.62–2.04)
TT (bb) 3 (1.5) 1 (1) – – 1.507 (0.15–14.68)
HWE P = 0.830
HPA3 T (a) 235 (58.8) 118 (59) 0.003 0.953 0.989 (0.70–1.39)
G (b) 165 (41.2) 82 (41) – – 1.010 (0.71–1.42)
TT (aa) 74 (37) 38 (38) 0.061 0.969 0.958 (0.58–1.57)
GT (ab) 87 (43.5) 42 (42) – – 1.063 (0.65–1.72)
GG (bb) 39 (19.5) 20 (20) – – 0.968 (0.53–1.76)
HWE P = 0.187
HPA4 G (a) 400 (100) 200 (100) – – –
A (b) 0 (0) 0 (0) – – –
GG (aa) 200 (100) 100 – – –
GA (ab) 0 (0) 0 – – –
AA (bb) 0 (0) 0 – – –
HWE P = 0
HPA5 G (a) 363 (90.7) 183 (91.5) 0.091 0.762 0.911 (0.49–1.66)
A (b) 37 (9.2) 17 (8.5) – – 1.097 (0.60–2.00)
GG (aa) 167 (83.5) 85 (85) 0.125 0.939 0.893 (0.45–1.73)
AG (ab) 29 (14.5) 13 (13) – – 1.135 (0.56–2.29)
AA (bb) 4 (2) 2 (2) – – 0.951 (0.17–5.28)
HWE P = 0.1
HPA6 G (a) 400 (100) 200 (100) – – –
A (b) 0 (0) 0 (0) – – –
GG (aa) 200 (100) 100 – – –
GA (ab) 0 (0) 0 – – –
AA (bb) 0 (0) 0 – – –
HWE P = 0
HPA9 G (a) 400 (100) 200 (100) – – –
A (b) 0 (0) 0 (0) – – –
GG (aa) 200 (100) 100 – – –
GA (ab) 0 (0) 0 – – –
AA (bb) 0 (0) 0 – – –
HWE P = 0
HPA15 C (a) 188 (47) 88 (44) 0.483 0.487 1.128 (0.80–1.58)
A (b) 212 (53) 112 (56) – – 0.886 (0.62–1.24)
CC (aa) 43 (21.5) 21 (21) 1.033 0.596 1.030 (0.57–1.85)
AC (ab) 102 (51) 46 (46) – – 1.221 (0.75–1.97)
AA (bb) 55 (27.5) 33 (33) – – 0.770 (0.45–1.29)
HWE P = 0.505
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Discussion
Here we evaluated the association of eight HPA poly-
morphisms with CAD in an Iranian population. Our 
findings indicated that the frequencies of all HPA 
alleles and genotypes were not significantly different 
between CAD patients and healthy controls. Moreover, 
there was no significant association of HPA haplotypes 
as independent risk factors with CAD development in 
the Iranian population. Nonetheless, after controlling 
for traditional CAD risk factors, our data supported 
the involvement of the HPA haplotype (1b/2a/3b) with 
CAD risk.
A study in a Japanese population reported no asso-
ciation of HPA1-6 genotypes with MI, which was in line 
with our results [18]. Our study is also consistent with 
a recent Tunisian study that reported the association of 
haplotypes containing HPA-1b allele, such as 1b/2a/3a 
and 1b/2a/3b with CAD risk. This association was still 
significant when it was adjusted for the traditional risk 
factors involved in the CAD development [19]. Our find-
ings are in line with the results of prior research per-
formed by Floyd et  al. in the UK. Their results did not 
find any association between HPA-1 polymorphism 
and CAD in patients over 45  years old. Nonetheless, 
Table 4 HPA haplotypes of HPA 1–3 in patients and controls
CAD coronary artery disease
*95% confidence interval for difference between Hap.freq case–control; If a CI does not contain 0, frequencies of haplotypes in case and control groups are 
significantly different at α = 0.05
a HPA haplotype (HPA1/HPA2/HPA3) frequency determined by the maximum likelihood method
b Fisher’s exact test
c Pc = corrected P, according to the Bonferroni method [Pc = 1 − (1 – P)n], where n = number of comparisons
Haplotypesa Frequencies Association test




χ2 P  valueb Pcc OR (95% CI)*
a a a 193 (0.482) 87 (0.437) 0.947 0.330597 0.910024 1.186 (0.84–1.67)
a a b 125 (0.313) 73 (0.363) 1.672 0.196024 0.729941 0.789 (0.55–1.13)
a b a 23 (0.058) 12 (0.059) 0.007 0.931565 1 0.969 (0.47–1.99)
a b b 22 (0.054) 6 (0.031) 1.639 0.200514 0.738865 1.804 (0.72–4.50)
b a a 17 (0.042) 15 (0.073) 2.743 0.097746 0.460523 0.547 (0.26–1.12)
b a b 15 (0.037) 3 (0.016) 2.023 0.155039 0.636068 2.357 (0.69–7.95)
b b a 2 (0.006) 4 (0.020) – – –
b b b 3 (0.008) 0 (0.000) – – –
Table 5 Univariate and multivariate regression for haplotypes of HPA1-3 polymorphisms
OR odds ratio, CI confidence interval, BP blood pressure, BMI body mass index, FBS fasting blood sugar, TG trigliserid, LDL low-density lipoprotein
a Adjusted for age, BMI, systolic and diastolic BP, FBS, total cholesterol, TG, and LDL concentrations
Univariate regression Multivariate regression
Z‑score P value OR (95% CI) Z‑score P value OR (95% CI)a
1a/2a/3a – – 1.00 – – 1.00
1a/2a/3b − 1.321 0.186 0.772 (0.53–1.13) − 0.750 0.454 0.838 (0.53–1.33)
1a/2b/3a − 0.385 0.700 0.864 (0.41–1.81) − 0.769 0.442 0.698 (0.28–1.75)
1a/2b/3b 1.052 0.293 1.653 (0.65–4.22) 0.118 0.905 1.075 (0.33–3.54)
1b/2a/3a − 1.782 0.075 0.511 (0.24–1.07) − 0.943 0.345 0.645 (0.26–1.60)
1b/2a/3b 1.259 0.208 2.254 (0.64–4.99) 2.436 0.015 2.792 (1.46–8.60)
BMI (kg/cm2) – – – 0.251 0.094 1.058 (0.98–1.08)
Sys.BP (mmHg) – – – 2.333 0.013 1.021 (1.00–1.04)
FBS (mg/dl) – – – 3.571 0.000 1.040 (1.03–1.05)
Total.Chol(mg/dl) – – – 3.306 0.000 2.008 (1.00–2.02)
LDL (mg/dl) – – – − 4.633 0.001 1.967 (0.96–1.98)
TG (mg/dl) – – – 2.817 0.000 1.017 (1.01–1.02)
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the presence of the HPA-1b allele was considered as a 
risk factor for development of cardiovascular diseases 
in younger patients (≤ 45  years). It appeared that the 
relative effect of this polymorphism is decreased con-
siderably with increasing in age and the presence of risk 
factors, such as blood pressure, diabetes, and cholesterol 
[20]. Nevertheless, our results are in apparent disagree-
ment with previous reports indicating a positive associa-
tion of HPA-1b and HPA-3b alleles with the risk of CAD 
in Tunisian patients [19], platelet hyper-reactivity in ACS 
[21, 22], and increased thrombotic complications [8, 23, 
24].
Our study confirms the study of Kvasnicka et  al. on 
HPA-1 and HPA-5 polymorphisms in a large case–con-
trol study involving 2369 cardiovascular patients with a 
history of the Vein thrombo embolism (VTE). Based on 
their statistical analysis, the allele frequency of the HPA-1 
and HPA-5 polymorphisms did not associate with sus-
ceptibility to CAD [25]. This paper also proposes robust 
evidences along with Wei et  al. study on HPA-1 and 
HPA-2 polymorphisms in Coronary heart disease (CHD) 
patients with more than 50% diameter stenosis. They 
showed that there was no relationship between the alleles 
and genotypes of HPA-1 and HPA-2 polymorphisms and 
the incidence of CAD [26]. In contrast, Zhang et al. pro-
posed the HPA-2b allele as a major risk factor for CHD 
disease in Chinese population. They reported that the 
frequency of HPA-2a/2b and HPA-2b/2b genotypes had a 
significant relationship with the incidence of the disease. 
Nonetheless, a meta-analysis of 25 case–control studies 
demonstrated a significant association between HPA-2b 
allele and HPA-2a/2b and HPA-2b/2b genotypes with 
incidence of CAD [27, 28].
Our findings shed additional light on the conception 
that, whereas individual genetic variations possess a con-
fining impact on CAD proneness, the haplotype analysis 
permits valid recognition of cases at high- and low-risk 
in the development of CAD [29, 30]. HPA-1a/1b, -2a/2b, 
-3a/3b are located on the GPIIIa, GPIbα, and GPIIb, 
respectively, which are the most frequent GPs and are 
important in the immunologic reactions. Genetic poly-
morphisms of these antigens may increase the adhesion 
tendency of the platelets to the harmed endothelium 
[11]. Therefore, specific HPA haplotypes may promote 
the activation, aggregation, and adhesion of platelets to 
the vessel endothelium during pathological conditions 
and the presence of risk factors like high blood pressure. 
These events may eventuate in the narrowing of the ves-
sel intima and development of atherosclerotic plaques 
through recruitment of further inflammatory leukocytes 
to the site of injured endothelium [9, 10, 31]. Our analy-
sis indicated increased risk of CAD susceptibility in cases 
harboring the HPA1b/HPA2a/HPA3b haplotype.
Based on our data, no associations of homozygous 
HPA-3b/3b genotype and HPA-3b allele were identified 
with predisposition to CAD in the Iranian population. 
These reports are in agreement with a study in German 
population, which indicated that there were no associa-
tions of both HPA-1 and HPA-3 variants, in the allelic, 
genotypic or haplotypic analysis, with risk of MI or CAD 
susceptibility [32]. However, it was observed that HPA-
3b/b had a protective role in the young male (< 56 years 
of age) from Korean CAD cases [33]. By contrast, this is 
in apparent disagreement with reports of Lekakis et  al., 
which indicated that HPA-3b allele and HPA-3b/3b gen-
otype did not associate with the intensity of coronary 
thrombosis in patients from Greece [34]. Although these 
incongruities remain to be speculated, they might stem 
from varieties in the diagnostic criteria of the patients or 
differences in the number of patients or control subjects 
included [18, 35], as well as the differences in the ethnic-
ity of the study participants [18, 32, 33, 36]. For instance, 
HPA-1b prevalence has been reported to be higher in 
Iranian healthy individuals (11%) than African (8%) [37], 
and Southeast Asians (1%) [38]. On the contrary, preva-
lence was lower than for Northern Europe (14–19%) [39, 
40], American populations (19.1%) [24], and Tunisians 
(45.4%), which is the utmost prevalence identified to date 
for all studied population ever [19].
Our data did not support any association of HPA poly-
morphisms with CAD in Iranian population. However, 
there was an association between the HPA haplotypes 
and CAD susceptibility after adjusting for traditional 
risk factors of CAD using the regression analysis mod-
els to determine the contribution of haplotypes for CAD 
development. It should be noted that the patients usu-
ally undergo a drug regiment to control blood pressure, 
glucose, and lipid after diagnosis of CAD. We used the 
recorded data of the patients before initiation of medica-
tion, not follow-up period. This issue could be contribut-
ing in obtaining solid and straightforward results in the 
analysis that could, otherwise, confer biased outcomes.
Among the limitations and caveats of the current study 
were the relatively small number of subjects, the retro-
spective case–control design of the study, and the HPA 
polymorphisms analyzed. As a consequence, the inter-
pretation of these data should be conducted cautiously 
considering the platelet function in CAD, as the platelet 
functions in healthy individuals probably differ from that 
of CAD patients, in which other items may also impress 
the physiology of platelets. We suggest a prospective 
study with a greater sample size for higher confidence 
level in approaching our results. We also suggest to inves-
tigate major adverse cardiac events within the formation 
of plaque in vessels and to explore their association with 
platelet antigens polymorphism.
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Conclusion
Considering all the results, this was the first replica-
tion study of HPA polymorphism association with CAD 
risk in an Iranian population. In spite of non-significant 
association of alleles, genotypes, and haplotypes of HPA 
polymorphisms with CAD risk, HPA1b/2a/3b haplotype 
was detected to be dependent disease risk after adjust-
ment for confounding factors. Being armed with the 
comprehensive knowledge of the functional implications 
of the genetic polymorphism in HPAs might be useful to 
stratify the patients based on the inherited risk factors for 
thrombosis, which in turn, might be beneficial in devis-
ing and developing novel treatment options to monitor 
and manage the arterial thrombosis in CAD patients. To 
comment with certainty on the implications of the HPA 
polymorphisms in the pathogenesis of CAD, further 
independent studies in different populations exerting 
larger sample sizes will be contributing.
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